Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies

Cardiovascular disease (CVD) has become an increasingly common limitation to effective anticancer therapy. Yet, whether CVD events were consistently reported in pivotal trials supporting contemporary anticancer drugs is unknown. The authors sought to evaluate the incidence, consistency, and nature o...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the American College of Cardiology 2020-02, Vol.75 (6), p.620-628
Hauptverfasser:	Bonsu, Janice M., Guha, Avirup, Charles, Lawrence, Yildiz, Vedat O., Wei, Lai, Baker, Brandee, Brammer, Jonathan E., Awan, Farrukh, Lustberg, Maryam, Reinbolt, Raquel, Miller, Eric D., Jneid, Hani, Ruz, Patrick, Carter, Rebecca R., Milks, Michael W., Paskett, Electra D., Addison, Daniel
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - adverse effects cancer clinical trials cardio-oncology cardiovascular disease Cardiovascular Diseases - chemically induced Cardiovascular Diseases - epidemiology Clinical Trials as Topic Drug Approval Humans reporting of adverse events Risk Management - statistics & numerical data U.S. Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!